|Table of Contents|

Effect of cardiac function in breast cancer patients with BRCA1/2 mutation treated with anthracyclines

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 02
Page:
252-255
Research Field:
Publishing date:

Info

Title:
Effect of cardiac function in breast cancer patients with BRCA1/2 mutation treated with anthracyclines
Author(s):
Xiong Ying1; Ma Hong'e2; Liu Baotang1; Zhu Xuejin3; Chen Gang4; Gao Xixv5
1.Department of Internal Medicine-Cardiovascular;2.Department of Respiratory Endocrinology;3.Department of Gastroenterology;4.Department of Neurology;5.Department of Traditional Chinese Medicine,the People's Hospital of Lueyang County,Shaanxi Hanzhong 724300,China.
Keywords:
BRCA1/2 gene; breast cancer; anthracyclines; left ventricular ejection fraction; global longitudinal strain
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2019.02.018
Abstract:
Objective:To evaluate the effect of cardiac function in breast cancer(BC) patients with BRCA1/2 mutation treated with anthracyclines.Methods：The subjects were 288 BC patients with normal blood pressure receiving long-term treatment of anthracycline.According to different genes,the patients were divided into BRCA1/2 gene mutation patients group (BRCA1/2 group,n=138) and sporadic patients group (sporadic group,n=150).Monitored and compared left ventricular ejection fraction (LVEF) and the overall longitudinal strain (GLS) of the two groups of patients by echocardiography.Results：The BRCA1/2 group had longer anthracycline treatment-to-enrollment time［(93.6±15.6)months vs (49.2±10.8) months,P＜0.001］.There were no significant differences in heart function and hemodynamic variables between two groups(all P＞0.05).Most of the patients had normal LVEF (92.4%) and GLS (83.3%).The differences of two groups with abnormal LVEF and GLS differences (P＞0.05).Conclusion：The cardiac risk with the use of standard-doses of adjuvant anthracyclines in treatment of BRCA1/2 mutation carriers with BC.

References:

［1］Mersch J,Jackson MA,Park M,et al.Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian［J］.Cancer,2015,121(2):269-275.
［2］Arts-de Jong M,Maas AH,Massuger LF,et al.BRCA1/2 mutation carriers are potentially at higher cardiovascular risk［J］.Crit Rev Oncol Hematol,2014,91(2):159-171.
［3］Bitler BG,Watson ZL,Wheeler LJ,et al.PARP inhibitors:Clinical utility and possibilities of overcoming resistance［J］.Gynecol Oncol,2017,147(3):695-704.
［4］Vanderstichele A,Busschaert P,Olbrecht S,et al.Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer［J］.Eur J Cancer,2017,86:5-14.
［5］Singh KK,Shukla PC,Quan A,et al.BRCA2 deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure［J］.J Biol Chem,2012,287(9):6604-6614.
［6］Tsou SH,Chen TM,Hsiao HT,et al.A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance［J］.PLoS One,2015,10(1):e0116747.
［7］Chen HY,Li J,Wang CS,et al.Left heart ejection fraction as a load-independent parameter for patients with mitral regurgitation［J］.J Heart Valve Dis,2017,26(4):437-446.
［8］Yingchoncharoen T,Agarwal S,Popovic ZB,et al.Normal ranges of left ventricular strain:A meta-analysis［J］.J Am Soc Echocardiogr,2013,26(2):185-191.
［9］Coute RA,Ehrenfeld JM,Gupta DK,et al.Electronically self-assessed functional capacity and exercise testing:A comparison of the Duke Activity Status Index and Patient-Reported Outcomes Measurement Information system tools［J］.Am Heart J,2017,188:82-86.
［10］Senthong V,Wu Y,Hazen SL,et al.Predicting long-term prognosis in stable peripheral artery disease with baseline functional capacity estimated by the Duke Activity Status Index［J］.Am Heart J,2017,184:17-25.
［11］Van Westerop LL,Arts-de Jong M,Hoogerbrugge N,et al.Cardiovascular risk of BRCA1/2 mutation carriers:A review［J］.Maturitas,2016,91:135-139.
［12］Yu JH,Lee JW,Son BH,et al.Characteristics of BRCA1/2 mutation-positive breast cancers in Korea:A comparison study based on multicenter data and the Korean breast cancer registry［J］.J Breast Cancer,2014,17(2):129-135.
［13］Cipolla MD.Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy［J］.Circulation,2016,133(4):e361.
［14］Qin A,Thompson CL.Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin［J］.J Cancer Surviv,2015,9(2):252-259.
［15］Zhao L,Qi Y,Xu L,et al.MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2［J］.Redox Biol,2017,15:284-296.
［16］Zhang YY,Yi M,Huang YP.Oxymatrine ameliorates doxorubicin-induced cardiotoxicity in rats［J］.Cell Physiol Biochem,2017,43(2):626-635.
［17］Sturgeon KM,Dean LT,Heroux M,et al.Commercially available lifestyle modification program:randomized controlled trial addressing heart and bone health in BRCA1/2+ breast cancer survivors after risk-reducing salpingo-oophorectomy［J］.J Cancer Surviv,2017,11(2):246-255.
［18］Minucci A,Scambia G,Santonocito C,et al.Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection:The experience at Gemelli hospital and a literature review［J］.Expert Rev Mol Diagn,2015,15(10):1383-1403.

Memo

Memo:
-
Last Update: 1900-01-01